Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed ovarian carcinoma

- Recurrent disease

- Known platinum-sensitive recurrent disease after no more than 2 prior salvage
regimens

- Measurable disease as defined by a target lesion and a CA125 level

- No epithelial ovarian carcinoma of low malignant potential

PATIENT CHARACTERISTICS:

Inclusion criteria:

- GOG performance status 0, 1, or 2

- Life expectancy > 6 months

- Absolute neutrophil count ≥ 1,500/uL

- Platelet count ≥ 100,000/uL

- Hemoglobin > 9.0 g/dL

- Creatinine ≤ 2.0 mg/dL

- Bilirubin ≤ 1.5 x upper limit of normal (ULN)

- SGOT and alkaline phosphatase ≤ 3 x ULN

- Neuropathy (sensory and motor) ≤ CTCAE grade 1

Exclusion criteria:

- GOG performance status 3 or 4

- Pregnant or breastfeeding

- History of hypersensitivity reactions attributed to a conventional formulation of
doxorubicin hydrochloride or the components of DOXIL®

- Abnormal LVEF as determined by gated cardiac radionucleotide scan (MUGA)

- Septicemia or severe infection

- Acute hepatitis or severe gastrointestinal bleeding

- Any of the following:

- Unstable angina

- Myocardial infarction within the past 6 months

- NYHA class II-IV heart failure

- Uncontrolled angina

- Severe uncontrolled ventricular arrhythmias

- Clinically significant pericardial disease

- Electrocardiographic evidence of acute ischemic or active conduction system
abnormalities

- Patients with evidence of abnormal cardiac conduction (e.g., bundle branch
block or heart block) are eligible if their disease has been stable for the
past six months

- Other invasive malignancies within the past 5 years except for nonmelanoma skin
cancer

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

- See Disease Characteristics

- At least 6 months since prior adjuvant regimen

- At least 4 weeks since prior salvage treatment

- May have received secondary cytoreduction for recurrent ovarian cancer

- May have received prior intraperitoneal therapy for ovarian cancer

- May have received no more than 2 prior platinum and taxane-based regimens

- May have received prior intraperitoneal platinum during front-line treatment

Exclusion criteria:

- Prior anthracycline dose exceeding 360 mg/m^2 for doxorubicin hydrochloride
(including DOXIL®) or 720 mg/m^2 for epirubicin hydrochloride

- Prior radiotherapy

- Prior intraperitoneal carboplatin or cisplatin as salvage treatment for recurrent
ovarian cancer

- Concurrent amifostine or other protective agents